SecurityGTMEY / Globe Telecom, Inc. (379549108)

Stock Insider Trading (from SEC Form 4)

Globe Telecom, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

GTMEY / Globe Telecom, Inc. insiders include .

Insider Roster

Insider Dir Off 10% Shares Owned

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

DICT passes major hurdle in search for third telco

20h business.inquirer.net
In choosing a new major telco player, the government oversight committee resolved on Friday to drop a proposed spectrum auction and adopt a set of rules that will reward participants seeking to give the highest committed level of service (HCLoS).

FuelCell Energy (FCEL) to Ramp Up Annual Output to 55MW

2018-07-19 zacks
FuelCell Energy, Inc. (FCEL - Free Report) has announced to increase its annual production from current 25 megawatts (MW) to 55MW, representing a rise of 120% in production rate. Also, the ramped-up production will add nearly 100 manufacturing jobs at its Torrington, CT manufacturing facility. The company undertook an expansion plan last year with two projects totaling 22.2MW, which has further provided it with the much-needed visibility to commence hiring and boost the production going forward. (67-0)

Alliance Data (ADS) Q2 Earnings Top, Tweaks Revenue View

2018-07-19 zacks
Alliance Data Systems Corporation’s (ADS - Free Report) operating earnings of $5.01 per share in the second quarter of 2018 surpassed the Zacks Consensus Estimate of $4.59. Also, the bottom line improved 31% year over year on the strength of Card Services and LoyaltyOne segment results. (2-0)

Union Pacific (UNP) Q2 Earnings Surpass Estimates, Up Y/Y

2018-07-19 zacks
Union Pacific Corporation’s (UNP - Free Report) second-quarter 2018 earnings of $1.98 per share surpassed the Zacks Consensus Estimate by 4 cents. The bottom line also expanded 36.6% on a year-over-year basis. Results were aided by higher revenues. (0-1)

Nokia's Nuage Networks Partners Philippines' Globe Telecom

2018-07-19 zacks
Nokia Corporation (NOK - Free Report) recently announced that its Nuage Networks has partnered with Globe Telecom to provide software-defined WAN (SD-WAN) services to large enterprise customers as well as small and midsize businesses across Philippines. Globe Telecom is a telecommunications service provider based in the archipelagic country in Southeast Asia. The Nuage Networks SD-WAN solution offers a range of branch routers and gateways at the remote site to facilitate seamless and automated connectivity to cloud networks. (12-0)